BioCentury | Oct 6, 2008
Product Development

Designs on NS5b

...program similar to the kind he performed while VP and head of antiviral research at Agouron Pharmaceuticals Inc....
BioCentury | Sep 24, 2007
Strategy

Ship, captain and crew

...2006, the company picked up several people who had been on the senior team at Agouron Pharmaceuticals Inc....
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...infections in patients with cystic fibrosis. Another one-horse show in the infectious disease space - Agouron Pharmaceuticals Inc....
BioCentury | Aug 8, 2005
Clinical News

Thymitaq nolatrexed: Phase III data

...has Fast Track and Orphan designations in the U.S. for this indication, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Apr 25, 2005
Clinical News

Thymitaq nolatrexed: Completed Phase III enrollment

...Phase III ETHECC trial. Thymitaq, which has Fast Track and Orphan designations, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Apr 20, 2005
Clinical News

Eximias enrolls Thymitaq Phase III

...The thymidylate synthase inhibitor, which has Fast Track and Orphan Drug designations, was in-licensed from Agouron...
BioCentury | Sep 27, 2004
Company News

OncoGenex Technologies board of directors update

...Cancer Appointed: Neil Clendeninn, former head of the clinical affairs group at Pfizer Inc. subsidiary Agouron Pharmaceuticals Inc. WIR...
BioCentury | Feb 2, 2004
Clinical News

Thymitaq nolatrexed: Phase III

...the ongoing trial. Thymitaq, which has Fast Track and Orphan Drug designation, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Nov 3, 2003
Company News

Chiron, Pfizer deal

...were not disclosed. As part of the deal, CHIR withdrew litigation filed in 1998 against Agouron...
BioCentury | Oct 28, 2003
Company News

Chiron, Pfizer HCV deal

...settled litigation involving Agouron , a division of PFE. CHIR has withdrawn litigation filed against Agouron...
Items per page:
1 - 10 of 350
BioCentury | Oct 6, 2008
Product Development

Designs on NS5b

...program similar to the kind he performed while VP and head of antiviral research at Agouron Pharmaceuticals Inc....
BioCentury | Sep 24, 2007
Strategy

Ship, captain and crew

...2006, the company picked up several people who had been on the senior team at Agouron Pharmaceuticals Inc....
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...infections in patients with cystic fibrosis. Another one-horse show in the infectious disease space - Agouron Pharmaceuticals Inc....
BioCentury | Aug 8, 2005
Clinical News

Thymitaq nolatrexed: Phase III data

...has Fast Track and Orphan designations in the U.S. for this indication, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Apr 25, 2005
Clinical News

Thymitaq nolatrexed: Completed Phase III enrollment

...Phase III ETHECC trial. Thymitaq, which has Fast Track and Orphan designations, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Apr 20, 2005
Clinical News

Eximias enrolls Thymitaq Phase III

...The thymidylate synthase inhibitor, which has Fast Track and Orphan Drug designations, was in-licensed from Agouron...
BioCentury | Sep 27, 2004
Company News

OncoGenex Technologies board of directors update

...Cancer Appointed: Neil Clendeninn, former head of the clinical affairs group at Pfizer Inc. subsidiary Agouron Pharmaceuticals Inc. WIR...
BioCentury | Feb 2, 2004
Clinical News

Thymitaq nolatrexed: Phase III

...the ongoing trial. Thymitaq, which has Fast Track and Orphan Drug designation, was licensed from Agouron Pharmaceuticals Inc....
BioCentury | Nov 3, 2003
Company News

Chiron, Pfizer deal

...were not disclosed. As part of the deal, CHIR withdrew litigation filed in 1998 against Agouron...
BioCentury | Oct 28, 2003
Company News

Chiron, Pfizer HCV deal

...settled litigation involving Agouron , a division of PFE. CHIR has withdrawn litigation filed against Agouron...
Items per page:
1 - 10 of 350